Clinical Trials Browser

Phase EARLY_PHASE1 × Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05553782 2026-01-26

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Phase EARLY_PHASE1 Recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT06645808 2025-12-29

VARTUTRACE

Phase EARLY_PHASE1 Recruiting

32 enrolled

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Osteosarcoma, Stomach Neoplasms

NCT05183048 2025-12-26

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

14 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06914999 2025-10-22

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

Phase EARLY_PHASE1 Recruiting

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT06819228 2025-10-03

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Phase EARLY_PHASE1 Recruiting

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Diseases, Mouth Neoplasms, Tongue Neoplasms

NCT06700070 2025-08-11

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

Phase EARLY_PHASE1 Recruiting

12 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

NCT06308913 2025-07-15

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

12 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT06366451 2025-01-20

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Phase EARLY_PHASE1 Recruiting

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05996432 2024-09-23

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Phase EARLY_PHASE1 Recruiting

48 enrolled

CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Brain Neoplasms

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Phase EARLY_PHASE1 Recruiting

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

Clinical Trials

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

VARTUTRACE

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies